+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), Drug Type (Over-The-Counter Drugs, Prescription Drugs), Route Of Administration, Drug Formulation, Distribution Channel - Global Forecast 2025-2030- Product Image
Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), Drug Type (Over-The-Counter Drugs, Prescription Drugs), Route Of Administration, Drug Formulation, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Anti-Obesity Therapeutics Market by Treatment Type (Medications, Treatments), Drug Type (Over-The-Counter Drugs, Prescription Drugs), Route Of Administration, Drug Formulation, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5305474
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Anti-Obesity Therapeutics Market is experiencing dynamic transformation as pharmaceutical innovation, device advances, and shifting regulatory factors accelerate the availability and adoption of new treatment options. This comprehensive market research delivers actionable intelligence tailored for senior decision-makers assessing investment and growth strategies in obesity therapeutics.

Market Snapshot: Anti-Obesity Therapeutics Market Growth and Opportunity

Between 2024 and 2025, the Anti-Obesity Therapeutics Market expanded from USD 10.79 billion to USD 11.69 billion and is projected to sustain an 8.59% compound annual growth rate, reaching USD 17.70 billion by 2030. This trajectory reflects the heightened global focus on the metabolic and clinical consequences of obesity, as well as increased investment in advanced therapeutics. Key contributors include rising obesity prevalence, favorable clinical outcomes from breakthrough drugs, and international efforts to widen accessibility for next-generation therapies.

Scope & Segmentation of the Anti-Obesity Therapeutics Market

This report provides a structured evaluation of the anti-obesity market, offering essential segmentation and competitive context. Stakeholders benefit from a detailed analysis across:

  • Treatment Types: Medications such as bupropion-naltrexone, liraglutide, orlistat, phentermine-topiramate, semaglutide, and tilzepatide; procedural solutions including adjustable gastric banding, endoscopic sleeve gastroplasty, and gastric bypass surgery.
  • Drug Types: Over-the-counter drugs and prescription medications, reflecting regulatory differences and varying requirements for medical supervision.
  • Route of Administration: Oral formats (capsules, tablets), parenteral administration (intravenous, subcutaneous), tailored to patient preferences and care delivery models.
  • Drug Formulations: Liquid, semi-solid, and solid dosage forms, each with implications for dosing flexibility and manufacturing scalability.
  • Distribution Channels: Hospitals & clinics pharmacies, online pharmacies, and retail pharmacies, reflecting both patient reach and regulatory oversight.
  • Geographic Coverage: Americas (covering the United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including markets such as the United Kingdom, Germany, Saudi Arabia, South Africa), and Asia-Pacific (with China, India, Japan, Australia, among others).
  • Key Companies: Alizyme PLC, Amgen Inc., Bristol-Myers Squibb, Currax Pharmaceuticals, Eli Lilly and Company, Merck & Co. Inc., Novo Nordisk A/S, Pfizer Inc., Takeda Pharmaceutical, and others, representing leading innovation, partnerships, and global reach.

Key Takeaways: Strategic Insights for Decision-Makers

  • Innovation in multi-agonist therapies and minimally invasive procedures is shifting the clinical standard of care and opening new commercialization pathways.
  • Integration of digital health, remote monitoring, and personalized nutrition platforms is reinforcing long-term patient adherence and outcomes.
  • Regional disparities in reimbursement, access, and regulatory pathways are influencing adoption rates and competitive positioning by country and sub-region.
  • Cross-sector collaboration between pharmaceutical companies, device innovators, and technology firms is driving ecosystem-level value creation and broadening treatment solutions.
  • Corporate strategies such as mergers, acquisitions, and joint ventures are shaping the landscape, fueling both technology integration and portfolio expansion.
  • Manufacturers are increasingly focused on localized production and flexible supply chain strategies to maintain business continuity and responsiveness to regional needs.

Tariff Impact: Navigating the Evolving U.S. Trade Environment

Forthcoming United States tariff measures for 2025 are set to increase costs for ingredient sourcing and device assembly, compelling pharmaceutical and device manufacturers to evaluate supply chain relocation, nearshoring, and partnership opportunities. These adjustments may drive shifts in pricing strategies, affect market margins, and prompt broader reassessment of manufacturing location versus regulatory compliance priorities. Effective mitigation will require robust tariff planning and multi-source supplier frameworks to sustain accessibility for end-users and protect against inventory disruptions.

Research Methodology & Data Sources

This analysis employs a rigorous, tiered methodology incorporating systematic secondary research, proprietary industry data, and structured interviews with leading endocrinologists, bariatric surgeons, and health economists. Quantitative findings are triangulated through clinical trial databases and real-world utilization data, and advanced analytics are used for scenario modeling and strategic forecasting. Qualitative assessments of partnership ecosystems and competitive behaviors further enhance insight accuracy.

Why This Report Matters to Industry Leaders

  • Enables informed strategic decisions through actionable segmentation, emerging technology trends, and evolving regulatory dynamics.
  • Equips organizations to anticipate and address regional, supply chain, and policy-driven risks that impact commercialization and long-term growth.

Conclusion

Senior executives and strategic planners will find this market research an essential guide to navigating complexity and capturing sustainable opportunities in the Anti-Obesity Therapeutics Market. The report's insights support evidence-driven investment and operational decisions in a rapidly evolving therapeutic landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Surge in GLP-1 receptor agonist approvals for chronic weight management in diverse populations
5.2. Rising investment in oral small molecule candidates targeting appetite regulatory pathways
5.3. Expansion of combination therapies pairing GLP-1 analogs with SGLT2 inhibitors for enhanced efficacy
5.4. Integration of digital therapeutics and remote monitoring to support patient weight loss adherence
5.5. Growing emphasis on gut microbiome modulation through prebiotic and postbiotic formulations in obesity
5.6. Development of peptide-based weight loss drugs with improved oral bioavailability and safety profiles
5.7. Regulatory pathways evolving to accommodate accelerated approval of novel obesity therapies based on surrogate endpoints
5.8. Emergence of personalized nutraceuticals targeting genetic predispositions to obesity and metabolic syndrome
5.9. Collaboration between pharmaceutical and tech startups to develop AI driven obesity treatment decision support tools
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Anti-Obesity Therapeutics Market, by Treatment Type
8.1. Introduction
8.2. Medications
8.2.1. Bupropion-Naltrexone
8.2.2. Liraglutide
8.2.3. Orlistat
8.2.4. Phentermine-Topiramate
8.2.5. Semaglutide
8.2.6. Tilzepatide
8.3. Treatments
8.3.1. Adjustable Gastric Banding
8.3.2. Endoscopic Sleeve Gastroplasty
8.3.3. Gastric Bypass Surgery
9. Anti-Obesity Therapeutics Market, by Drug Type
9.1. Introduction
9.2. Over-The-Counter Drugs
9.3. Prescription Drugs
10. Anti-Obesity Therapeutics Market, by Route Of Administration
10.1. Introduction
10.2. Oral Administration
10.2.1. Capsules
10.2.2. Tablets
10.3. Parenteral Administration
10.3.1. Intravenous
10.3.2. Subcutaneous
11. Anti-Obesity Therapeutics Market, by Drug Formulation
11.1. Introduction
11.2. Liquid Dosage Forms
11.3. Semi-Solid Dosage Forms
11.4. Solid Dosage Forms
12. Anti-Obesity Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Hospitals & Clinics Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas Anti-Obesity Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Anti-Obesity Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Anti-Obesity Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Alizyme PLC
16.3.2. Amgen Inc.
16.3.3. Arena Pharmaceuticals Inc.
16.3.4. Boehringer Ingelheim International GmbH
16.3.5. Bristol-Myers Squibb Company
16.3.6. Currax Pharmaceuticals LLC
16.3.7. Eisai Co. Ltd.
16.3.8. Eli Lilly and Company
16.3.9. F. Hoffmann-La Roche Ltd
16.3.10. FlaxoSithKline plc.
16.3.11. GlaxoSmithKline PLC
16.3.12. Johnson & Johnson Services Inc.
16.3.13. Merck & Co. Inc.
16.3.14. Nalpropion Pharmaceuticals Inc.
16.3.15. Norgine B.V.
16.3.16. Novartis AG
16.3.17. Novo Nordisk A/S
16.3.18. Orexigen Therapeutics Inc.
16.3.19. Pfizer Inc.
16.3.20. Rhythm Pharmaceuticals, Inc.
16.3.21. Sanofi S.A.
16.3.22. SHIONOGI & Co., Ltd.
16.3.23. Takeda Pharmaceutical Company Limited
16.3.24. Vivus Inc.
16.3.25. Zydus Lifesciences Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ANTI-OBESITY THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. ANTI-OBESITY THERAPEUTICS MARKET: RESEARCHAI
FIGURE 26. ANTI-OBESITY THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 27. ANTI-OBESITY THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 28. ANTI-OBESITY THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. ANTI-OBESITY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 117. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 118. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 119. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 120. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 121. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 122. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 123. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 124. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 125. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 126. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 127. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 130. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 131. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
TABLE 132. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2030 (USD MILLION)
TABLE 133. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 134. CANADA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 135. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 136. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 137. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 138. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 139. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 140. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 141. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 142. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 143. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 148. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 149. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
TABLE 150. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2030 (USD MILLION)
TABLE 151. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. MEXICO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 172. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 210. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 228. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 229. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 230. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 231. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 232. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 233. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 234. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 235. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 236. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 237. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
TABLE 242. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2030 (USD MILLION)
TABLE 243. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. GERMANY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 246. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 247. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 248. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 249. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 250. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 251. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 252. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 253. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 254. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 255. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
TABLE 260. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2030 (USD MILLION)
TABLE 261. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. FRANCE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 264. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 282. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 283. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 284. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 285. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 286. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 287. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 288. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 289. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 290. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 291. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 294. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 295. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
TABLE 296. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2030 (USD MILLION)
TABLE 297. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. ITALY ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 300. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 301. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
TABLE 302. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2030 (USD MILLION)
TABLE 303. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
TABLE 304. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2030 (USD MILLION)
TABLE 305. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 306. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 307. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 308. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 309. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 310. SPAIN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2030 (USD MILLION)

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Anti-Obesity Therapeutics market report include:
  • Alizyme PLC
  • Amgen Inc.
  • Arena Pharmaceuticals Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Currax Pharmaceuticals LLC
  • Eisai Co. Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • FlaxoSithKline plc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Nalpropion Pharmaceuticals Inc.
  • Norgine B.V.
  • Novartis AG
  • Novo Nordisk A/S
  • Orexigen Therapeutics Inc.
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Sanofi S.A.
  • SHIONOGI & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Vivus Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages197
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.69 Billion
Forecasted Market Value ( USD ) by 2030 $ 17.7 Billion
Compound Annual Growth Rate8.5%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Anti-obesity Prescription Drugs Market by Drug Class (Amylin Analogs, GLP-1 Agonists, Lipase Inhibitors), Administration Route (Injectables, Orals), Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Anti-obesity Prescription Drugs Market by Drug Class (Amylin Analogs, GLP-1 Agonists, Lipase Inhibitors), Administration Route (Injectables, Orals), Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Obesity Treatment Market by Treatment Type (Pharmacotherapy, Surgical Procedures), Drug Class (Appetite Suppressants, GLP-1 Receptor Agonists, Lipase Inhibitors), Route of Administration, Patient Age Group, Distribution Channel, End-User - Global Forecast 2025-2030 - Product Image

Obesity Treatment Market by Treatment Type (Pharmacotherapy, Surgical Procedures), Drug Class (Appetite Suppressants, GLP-1 Receptor Agonists, Lipase Inhibitors), Route of Administration, Patient Age Group, Distribution Channel, End-User - Global Forecast 2025-2030

  • Report
  • 188 Pages
  • Global
From
Obesity Market Report and Forecast 2025-2034 - Product Image

Obesity Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Digital Health for Obesity - Global Strategic Business Report - Product Image

Digital Health for Obesity - Global Strategic Business Report

  • Report
  • 281 Pages
  • Global
From
Weight Loss And Obesity Management Global Market Report 2025 - Product Image

Weight Loss And Obesity Management Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.